- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04578847
A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) (READIT)
Prospective Non-randomized Stratified Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) in Adults With Ph+ Chronic Myeloid Leukemia With Stable Deep Molecular Response
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The duration of the dose reduction phase will be 12 months. This phase will have two stage of 6 months, respectively.
The dose of imatinib, nilotinib, dasatinib or bosutinib will be reduced by 25-50% on the first stage, and by another 25% on the second stage.
- The initial dose of imatinib will be 400 mg daily. The dose will be reduced by 300 mg daily on the first stage, by 200 mg daily - on the second stage.
- The initial dose of nilotinib will be 300 or 400 mg twice daily. The dose will be reduced by 400 mg daily on the first stage, by 200 mg daily - on the second stage.
- The initial dose of dasatinib will be 100 or 140 mg daily. The dose will be reduced by 50 mg daily on the first stage, by 25 mg daily - on the second stage.
- The initial dose of bosutinib will be 500 mg daily. The dose will be reduced by 300 mg daily on the first stage, by 200 mg daily - on the second stage.
All patients with stable deep molecular response (at least 2 years) will be included in treatment free remission phase (TFR-phase). The duration of TFR-phase will be 24 months.
The CML patients can enter the study already on reduced doses TKI, if they will meet the inclusion criteria.
It is possible to include patients, who have already received therapy with reduced doses of TKI. The duration of TKI therapy with reduced doses of 1 stage should be at least 6 months, if TKI doses meet of stage 1. The duration of TKI therapy with reduced doses of 2 stage should be for at least 6 months and the general duration of TKI therapy with reduced doses should be for at least 12 months, if TKI doses meet of stage 2.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Moscow, Russian Federation
- National Research Center for Hematology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- CML in chronic phase.
- TKI treatment for at least 3 years.
- DMR (BCR-ABL≤0.01%) for at least 1 year, MMR (BCR-ABL≤0.1%) for at least 2 years
- At least 3 molecular results over the preceding 24 months, which confirm the presence of MMR and DMR
- Written Informed Consent
- CML patients with DMR for at least 1 years and MMR for at least 2 years after STOP TKI in anamnesis.
For patients who are on the reduced dose TKI (1 stage) at the time of inclusion in the study
1. The duration of therapy at reduced doses of TKI phase I is at least 6 months.
For patients on the reduced dose TKI (2 stage, before TFR phase) at the time of inclusion in the study
- DMR (BCR-ABL≤0.01%) for at least 2 years
- The duration of therapy at reduced doses of TKI phase 1 is for at least 6 months, the total duration of therapy at reduced doses is for at least 12 months.
Exclusion Criteria:
- Age under 18
- ECOG >2
- CML in accelerated phase or blast crisis at any time
- Lack of Written Informed Consent
- Pregnant or lactating women
- Incapacity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: The TKI dose reduction
Imatinib, nilotinib, dasatinib or bosutinib; the two stage of TKI dose reduction phase for 12 months (6 months and 6 months, respectively).
|
Initial dose - 400 mg daily.
If on imatinib, the dose should be decreased to 300 mg daily on the first stage, to 200 mg daily - on the second stage.
Initial dose - 300 or 400 mg twice daily.
If on nilotinib to 400mg daily on the first stage, to 200 mg daily - on the second stage.
Initial dose 100 or 140 mg daily.
If on dasatinib then to 50 mg daily on the first stage, to 25 mg daily - on the second stage.
Initial dose 500 mg daily.
If on bosutinib, the dose should be reduced to 300 mg daily on the first stage, to 200 mg daily on the second stage.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival, survival without molecular relapse
Time Frame: 37 months
|
37 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of patients with molecular relapse who achieved MMR and DMR after the resumption TKI therapy in standard doses
Time Frame: 37 months
|
37 months
|
|
The proportion of patients who resolved the adverse events after TKI dose reduction and discontinuation of TKI therapy
Time Frame: 37 months
|
37 months
|
|
The proportion of patients who have TKI withdrawal syndrome after TKI dose reduction and discontinuation of TKI therapy.
Time Frame: 37 months
|
37 months
|
|
Clinical factors, that affect the preservation of MMR after TKI dose reduction and discontinuation of therapy TKI.
Time Frame: 37 months
|
sex (male, female)
|
37 months
|
Clinical factor, that affect the preservation of MMR after TKI dose reduction and discontinuation of therapy TKI.
Time Frame: 37 months
|
age
|
37 months
|
Clinical factor, that affect the preservation of MMR after TKI dose reduction and discontinuation of therapy TKI.
Time Frame: 37 months
|
risk group (Sokal, ELTS) at the time of diagnosis
|
37 months
|
Clinical factor, that affect the preservation of MMR after TKI dose reduction and discontinuation of therapy TKI.
Time Frame: 37 months
|
duration of previous TKI treatment
|
37 months
|
Biological factor, that affect the preservation of MMR after TKI dose reduction and discontinuation of therapy TKI.
Time Frame: 37 months
|
Duration of molecular response
|
37 months
|
Biological factor, that affect the preservation of MMR after TKI dose reduction and discontinuation of therapy TKI.
Time Frame: 37 months
|
Molecular response at the time of inclusion in the study
|
37 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Anna Turkina, Professor, National Research Center for Hematology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Imatinib Mesylate
- Dasatinib
Other Study ID Numbers
- READIT-2020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Myeloid Leukemia
-
Newcastle UniversityBristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Newcastle-upon-Tyne... and other collaboratorsCompletedMyeloid Leukemia, Chronic, Chronic PhaseUnited Kingdom
-
Asan Medical CenterTerminatedLeukemia, Chronic Myeloid | Myeloid Leukemia, Chronic, Chronic Phase | Myeloid Leukemia, Chronic, Accelerated PhaseKorea, Republic of
-
Bristol-Myers SquibbTerminatedLeukemia, Myeloid, ChronicSweden, United Kingdom, Russian Federation, France, Germany, Belgium, Portugal, Finland, Norway, Spain, Italy
-
University of BolognaCompletedMyeloid Leukemia, Chronic, Chronic-PhaseItaly
-
Bristol-Myers SquibbWithdrawnMyeloid Leukemia, Chronic, Chronic-PhaseUnited States
-
PETHEMA FoundationCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteIncyte Corporation; H. Jean Khoury Cure CML ConsortiumRecruitingChronic Myeloid Leukemia, Chronic Phase | Chronic Phase Chronic Myeloid LeukemiaUnited States
-
Fundacion Espanola para la Curacion de la Leucemia...Pfizer; Roche Farma, S.ATerminatedChronic Phase-Chronic Myeloid LeukemiaSpain
-
TakedaActive, not recruitingMyeloid Leukemia, Chronic, Chronic PhaseUnited States, Spain, Taiwan, Australia, Canada, Russian Federation, Sweden, Switzerland, Germany, United Kingdom, Poland, Korea, Republic of, Argentina, Hong Kong, Singapore, Italy, Chile, Czechia, Denmark, France, Portugal
-
Associazione Italiana Pazienti Leucemia Mieloide...Not yet recruitingChronic Myeloid Leukemia (CML)Italy
Clinical Trials on Imatinib
-
Centre Leon BerardCompletedGastrointestinal Stromal Tumors | Resected Gastrointestinal Stromal Tumors | Non-metastatic | High Risk of Recurrence | KIT Gene MutationFrance
-
Scandinavian Sarcoma GroupCompleted
-
Sarit AssoulineNovartisRecruitingChronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | Chronic Myeloid Leukemia, BCR/ABL-PositiveCanada
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedChronic Myeloid LeukemiaChina
-
Seoul St. Mary's HospitalNovartisUnknownChronic Myeloid LeukemiaKorea, Republic of
-
M.D. Anderson Cancer CenterNovartisCompletedGastrointestinal Stromal TumorsUnited States
-
Novartis PharmaceuticalsCompletedGastrointestinal Stromal TumorsUnited States, France, Belgium, Germany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMelanoma | Skin NeoplasmsUnited States
-
University of Auckland, New ZealandLeukaemia & Blood Cancer New ZealandActive, not recruiting
-
Novartis PharmaceuticalsCompletedPulmonary Arterial HypertensionAustria, Germany, United States, United Kingdom